Protection by intranasal immunization of a nef-deleted, nonpathogenic SHIV against intravaginal challenge with a heterologous pathogenic SHIV

Virology

Volumn 298, Issue 2, 2002, Pages 306-316

  Enose, Yoshimi ^a   Ui, Masahiro ^a   Miyake, Ariko ^a   Suzuki, Hajime ^a   Uesaka, Hiromi ^a   Kuwata, Takeo ^a   Kunisawa, Jun ^b   Kiyono, Hiroshi ^b   Takahashi, Hidemi ^a,c   Miura, Tomoyuki ^a   Hayami, Masanori ^a  

^a KYOTO UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Intravaginal infection; Mucosal immunity; SHIV

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; NEF PROTEIN; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; GENE DELETION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNIZATION; INFECTION PREVENTION; MACACA; MUCOSAL IMMUNITY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; VAGINITIS; VIRUS ATTENUATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; SIMIAE; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0036374965     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2002.1440     Document Type: Article

References (46)

1. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
2. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions
3. Antibodies to human immunodeficiency virus in vaginal secretions of heterosexual women
4. Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine
5. Mucosal immunization of cynomolgus macaques with two serotypes of live poliovirus vectors expressing simian immunodeficiency virus antigens: Stimulation of humoral, mucosal, and cellular immunity
6. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene
7. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes
8. Restriction of viral population by intravaginal infection of simian immunodeficiency viruses in macaque monkeys
9. Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization
10. Mucosal transmission of pathogenic CXCR4-utilizing SHIVSF33A variants in rhesus macaques
11. Infection of an HIV-1/SIVmac chimeric virus having HIV-1 env to macaque monkeys via the vaginal cavity
12. Protection of monkeys vaccinated with vpr- and/or nef-defective simian immunodeficiency virus strain mac/human immunodeficiency virus type 1 chimeric viruses: A potential candidate live-attenuated human AIDS vaccine
13. Nasal immunization of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues
14. Animal model of mucosally transmitted human immunodeficiency virus type 1 disease: Intravaginal and oral deposition of simian/human immunodeficiency virus in macaques results in systemic infection, elimination of CD4+ T cells, and AIDS
15. Oral immunization of macaques with attenuated vaccine virus induces protection against vaginally transmitted AIDS
16. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: Inverse relationship of degree of protection with level of attenuation
17. Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys
18. HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers
19. Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts
20. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women
21. Construction of human immunodeficiency virus 1/simian immunodeficiency virus strain mac chimeric viruses having vpr and/or nef of different parental origins and their in vitro and in vivo replication
22. Induction of mucosal and systemic immunity to a recombinant simian immunodeficiency viral protein
23. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques
24. Antiviral cytotoxic T lymphocytes in vaginal mucosa of simian immunodeficiency virus-infected rhesus macaques
25. Anti-gp160 IgG and IgA antibodies associated with a large increase in total IgG in cervicovaginal secretions from human immunodeficiency virus type 1-infected women
26. Vaginal transmission of chimeric simian/human immunodeficiency viruses in rhesus macaques
27. Targeted lymph-node immunization with whole inactivated simian immunodeficiency virus (SIV) or envelope and core subunit antigen vaccines does not reliably protect rhesus macaques from vaginal challenge with SIVmac251
28. Protection against vaginal SIV transmission with microencapsulated vaccine
29. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
30. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
31. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals
32. Genital secretory immune response to chronic simian immunodeficiency virus (SIV) infection: A comparison between intravenously and genitally inoculated rhesus macaques
33. Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239
34. HIV-1 induces cytotoxic T lymphocytes in the cervix of infected women
35. Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice
36. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro
37. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys
38. An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys
39. Intranasal delivery of recombinant parvovirus-like particles elicits cytotoxic T-cell and neutralizing antibody responses
40. Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: Determinants of high virus loads and CD4 cell killing
41. Mucosal immunity to HIV-1: Systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A)
42. Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses
43. Plasma SIV RNA viral load determination by real-time quantification of product generation in reverse transcriptase-polymerase chain reaction
44. Protective immunity of gene-deleted SHIVs having an HIV-1 Env against challenge infection with a gene-intact SHIV
45. Protection of macaques against a SHIV with a homologous HIV-1 Env and a pathogenic SHIV-89.6P with a heterologous Env by vaccination with multiple gene-deleted SHIVs
46. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge